Checkpoint inhibitor

Merus Announces Publication in Nature Communications on MCLA-145’s Novel Mechanism of Action Promoting Tumor Immunity and Context Dependent T-Cell Costimulation

Retrieved on:

Wednesday, July 21, 2021

Medical specialties, Clinical medicine, Medicine, Immunology, Immune system, Cancer immunotherapy, Bispecific monoclonal antibody, Antibody, PD-L1, Checkpoint inhibitor, Priming

(Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced the novel mechanism of action (MOA) of MCLA-145, the Companys clinical stage Biclonics T-cell agonist.

Key Points:

(Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced the novel mechanism of action (MOA) of MCLA-145, the Companys clinical stage Biclonics T-cell agonist.
The unique immunostimulatory mechanism of action of MCLA-145 was published in Nature Communications on June 21, 2021, titled A human CD137PD-L1 bispecific antibody promotes anti-tumor immunity via context dependent T cell costimulation and checkpoint blockade.
MCLA-145 was identified by screening hundreds of bispecific IgG antibodies for immune activation via PD-L1 engagement among other characteristics.
Furthermore, MCLA-145 was shown to enhance T cell priming and to promote long-term T cell immunity.

NOXXON Pharma Enters Second Clinical Collaboration With MSD to Evaluate NOX-A12 in Combination With KEYTRUDA® (Pembrolizumab) in Upcoming Phase 2 Pancreatic Cancer Study

Retrieved on:

Wednesday, July 21, 2021

This Phase 2 study will evaluate the safety and efficacy of NOX-A12, NOXXONs anti-CXCL12 agent, in combination with KEYTRUDA and two different chemotherapy regimens in patients with microsatellite stable pancreatic cancer.

Key Points:

This Phase 2 study will evaluate the safety and efficacy of NOX-A12, NOXXONs anti-CXCL12 agent, in combination with KEYTRUDA and two different chemotherapy regimens in patients with microsatellite stable pancreatic cancer.
The vast majority of pancreatic cancer patients have microsatellite stable tumors which are resistant to checkpoint inhibitor monotherapy.
MSD will provide pembrolizumab and expert advice for the study protocol, while NOXXON will sponsor the trial that will be conducted in clinical centers in the US and Europe.
NOX-A12 is currently developed in second-line pancreatic cancer in combination with Keytruda and in glioblastoma in combination with radiotherapy.

GigaGen Publishes Research Describing Novel Mechanism of Action and Therapeutic Potential of its anti-CTLA-4 Drug Candidate, GIGA-564

Retrieved on:

Wednesday, July 14, 2021

Clinical medicine, Medicine, Branches of biology, T cells, Immune system, Clusters of differentiation, Cancer immunotherapy, Antineoplastic drugs, Checkpoint inhibitor, Regulatory T cell, CTLA-4, Chemotherapy

The publication describes the novel mechanism of action of its anti-CTLA-4 drug candidate, GIGA-564, selected due to its reduced checkpoint inhibition, which resulted in superior anti-tumor activity and lower toxicity in murine models compared to commercially available anti-CTLA-4 drugs.

Key Points:

The publication describes the novel mechanism of action of its anti-CTLA-4 drug candidate, GIGA-564, selected due to its reduced checkpoint inhibition, which resulted in superior anti-tumor activity and lower toxicity in murine models compared to commercially available anti-CTLA-4 drugs.
We selected GIGA-564 due to its minimal checkpoint inhibition and its ability to deplete intratumoral Tregs in the tumor.
GigaGen is advancing transformative antibody drugs for immune deficiency, infectious diseases and checkpoint resistant cancers by leveraging industry-leading, single-cell technologies.
In addition, GigaGens lead oncology asset, GIGA-564, is an anti-CTLA-4 monoclonal antibody that has demonstrated improved anti-tumor efficacy in vivo through a unique mechanism of action.

Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immune Checkpoint Inhibitor-related Adverse Events

Retrieved on:

Wednesday, July 14, 2021

Clinical medicine, Medicine, Cancer, Immune system, Cancer immunotherapy, Antineoplastic drugs, Checkpoint inhibitor, Immune checkpoint, Chemotherapy, Head and neck cancer, Melanoma, PD-1 and PD-L1 inhibitors

ICIs are treatments that unleash the immune system against cancer, but the same mechanisms that underpin their effective anti-tumor properties may cause unique toxicities, specifically immune-related adverse events (irAEs).

Key Points:

ICIs are treatments that unleash the immune system against cancer, but the same mechanisms that underpin their effective anti-tumor properties may cause unique toxicities, specifically immune-related adverse events (irAEs).
"I am pleased to share in the excitement of SITC's long-awaited clinical practice guideline on immune checkpoint inhibitor-related adverse events."
SITC has published CPGs for acute leukemia , bladder carcinoma, cutaneous melanoma , head and neck squamous cell carcinoma , immune checkpoint inhibitor-related adverse events , immune effector cell-related adverse events , lymphoma , multiple myeloma, non-small cell lung cancer , prostate cancer and renal cell carcinoma.
SITC thanks the American Society of Transplantation and Cellular Therapy (ASTCT) and all participating organizations for providing representatives to serve on SITC's Immune Checkpoint Inhibitor-Related Adverse Events Expert Panel and for their efforts in developing this clinical practice guideline.

Sesen Bio Announces Productive Late-Cycle Meeting with the FDA for Vicineum™

Retrieved on:

Wednesday, July 14, 2021

Biotechnology, Pharmaceutical, Health, Oncology, Clinical medicine, Medicine, Cancer, Cancer immunotherapy, Immune system, Oncology, Cancer treatments, Antineoplastic drugs, Checkpoint inhibitor, Chemotherapy, Vicineum™, Sesen Bio, VICINEUM™, SESEN BIO

We are very pleased with the outcome of the Late-Cycle Meeting and continue to feel encouraged by the level of engagement from the FDA in our ongoing discussions regarding the BLA for Vicineum, said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio.

Key Points:

We are very pleased with the outcome of the Late-Cycle Meeting and continue to feel encouraged by the level of engagement from the FDA in our ongoing discussions regarding the BLA for Vicineum, said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio.
Additionally, Sesen Bio believes that cancer cell-killing properties of Vicineum promote an anti-tumor immune response that may potentially combine well with immuno-oncology drugs, such as checkpoint inhibitors.
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer.
Sesen Bio continues to monitor the rapidly evolving environment regarding the potential impact of the COVID-19 pandemic on our Company.

Active Biotech’s partner NeoTX will host KOL webinar on overcoming check point Inhibitor resistance

Retrieved on:

Thursday, July 8, 2021

Clinical medicine, Medicine, Cancer, Oncology, Cancer immunotherapy, Immune system, Chemotherapy, Checkpoint inhibitor

Lund, July 8 2021 - Active Biotech (Nasdaq Stockholm: ACTI) today provided information that its partner in the naptumomab project, NeoTX will host a key opinion leader (KOL) webinar on overcoming checkpoint inhibitor resistance on Wednesday, July 14th at 10 am eastern time (ET)

Key Points:

Lund, July 8 2021 - Active Biotech (Nasdaq Stockholm: ACTI) today provided information that its partner in the naptumomab project, NeoTX will host a key opinion leader (KOL) webinar on overcoming checkpoint inhibitor resistance on Wednesday, July 14th at 10 am eastern time (ET)
The webinar will feature a presentation by KOL Mario Sznol, MD, Yale Cancer Center, who will discuss New Frontiers for Checkpoint Inhibitors in Immuno-Oncology.
NeoTX's management will also give an update on their Tumor Targeted Superantigen (TTS) platforms lead candidate, naptumomab estafenatox (naptumomab) in overcoming resistance.
Naptumomab is being evaluated in combination with chemotherapy, checkpoint inhibitors and CAR T. Dr. Sznol and NeoTX management will be available to answer questions following the formal presentations.
Since 2016, Active Biotech has a licensing agreement with NeoTX Therapeutics Ltd. for the worldwide development and commercialization of naptumomab for cancer therapy.

NeoTX Hosting Key Opinion Leader Webinar on Overcoming Check Point Inhibitor Resistance

Retrieved on:

Wednesday, July 7, 2021

Clinical medicine, Cancer immunotherapy, Medicine, Oncology, Checkpoint inhibitor

REHOVOT, Israel, July 07, 2021 (GLOBE NEWSWIRE) -- NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, announced today that it will host a key opinion leader (KOL) webinar on overcoming checkpoint inhibitor resistance on Wednesday, July 14, 2021 at 10am Eastern Time.

Key Points:

REHOVOT, Israel, July 07, 2021 (GLOBE NEWSWIRE) -- NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, announced today that it will host a key opinion leader (KOL) webinar on overcoming checkpoint inhibitor resistance on Wednesday, July 14, 2021 at 10am Eastern Time.
The webinar will feature a presentation by KOL Mario Sznol, MD, Yale Cancer Center, who will discuss New Frontiers for Checkpoint Inhibitors in Immuno-Oncology.
NeoTX's management will also give an update on their Tumor Targeted Superantigen (TTS) platforms lead candidate, naptumomab estafenatox (NAP) in overcoming resistance.
NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform.

Ultimovacs Announces Review Article Highlighting Telomerase-based Therapeutic Cancer Vaccines

Retrieved on:

Monday, July 5, 2021

Clinical medicine, Medicine, Branches of biology, Vaccination, Cancer immunotherapy, Immunotherapy, Virotherapy, Telomerase, Cancer vaccine, Vaccine, Checkpoint inhibitor

OSLO, Norway, July 05, 2021 (GLOBE NEWSWIRE) -- Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced the publication of a review of telomerase-based therapeutic cancer vaccines including the Companys universal cancer vaccine, UV1.

Key Points:

OSLO, Norway, July 05, 2021 (GLOBE NEWSWIRE) -- Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced the publication of a review of telomerase-based therapeutic cancer vaccines including the Companys universal cancer vaccine, UV1.
The article focusses on the synergy between telomerase-based cancer vaccines and checkpoint inhibitors.
This latest article articulates the rationale for using telomerase-targeting cancer vaccines as a key to unlock the full potential of checkpoint inhibitors, stated Carlos de Sousa, Chief Executive Officer at Ultimovacs.
With a broad Phase II program, Ultimovacs aims to clinically demonstrate UV1s impact in multiple cancer types in combination with other immunotherapies.

Merck Provides Update on KEYTRUDA® (pembrolizumab) Indication in Third-Line Gastric Cancer in the US

Retrieved on:

Thursday, July 1, 2021

Patients being treated with KEYTRUDA for metastatic gastric cancer in the third- or further-line setting should discuss their care with their health care provider.

Key Points:

Patients being treated with KEYTRUDA for metastatic gastric cancer in the third- or further-line setting should discuss their care with their health care provider.
The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H central nervous system cancers have not been established.
KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
At Merck, the potential to bring new hope to people with cancer drives our purpose and supporting accessibility to our cancer medicines is our commitment.

Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors

Retrieved on:

Wednesday, June 23, 2021

Clinical medicine, Cancer treatments, Medicine, Cancer immunotherapy, Immune system, Clusters of differentiation, Programmed cell death protein 1, PD-L1, Checkpoint inhibitor, PD-1 and PD-L1 inhibitors

To be eligible for the trial, patients must have disease that is relapsed or refractory to an anti-PD-1 or PD-L1 therapy.

Key Points:

To be eligible for the trial, patients must have disease that is relapsed or refractory to an anti-PD-1 or PD-L1 therapy.
RTX-240 is designed to activate and expand a patients own immune cells to mount a broad and potent anti-tumor response.
Combining an immune agonist with a PD-1 checkpoint inhibitor has the potential to prevent the cancer from evading the immune response.
The monotherapy arm of the trial in advanced solid tumors includes a Phase 2 expansion in specified tumor types.